Halozyme Therapeutics, Inc.
HALONASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $15.10B
- P/E (TTM)
- 36.50
- Forward P/E
- 49.10
- Dividend yield
- -
- 52-week range
- $61.23$125.10
- Volume (live)
- -
- Avg. volume (3M)
- 2.60M
Halozyme Therapeutics (HALO) Stock Price & Financial Analysis
Halozyme Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $121.62 - $124.91 |
|---|---|
| 52-Week High | $125.10 |
| 52-Week Low | $61.23 |
| Open | $124.72 |
| Volume (last close) | 5.10M |
| Average Volume (3M) | 2.60M |
| Revenue (TTM) | 1.66B |
|---|---|
| Net Income (TTM) | 413.60M |
| Free Cash Flow (TTM) | 806.22M |
| EPS (TTM) | $3.42 |
| Profit Margin | 24.86% |
| Operating Margin | 55.95% |
| Return on Equity (ROE) | 288.13% |
| Debt to Equity | 14.95 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 15.10B |
|---|---|
| Shares Outstanding | 121.22M |
| P/E Ratio (TTM) | 36.50 |
| Forward P/E | 49.10 |
| Price to Sales (P/S) | 9.07 |
| Price to Book (P/B) | 105.17 |
| EV/EBITDA | 24.00 |
| 50-Day MA | $109.74 |
|---|---|
| 200-Day MA | $81.16 |
| 1-Year Change | +86.20% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Halozyme Therapeutics at a Glance
As of the Oct 22, 2026 close, Halozyme Therapeutics (HALO) has a market capitalization of $15.10B. The stock trades at 36.5× trailing earnings, 49.1× forward earnings and 9.1× sales. Over the trailing twelve months it earned $413.60M on revenue of $1.66B (a 24.9% profit margin) and generated $806.22M of free cash flow. Revenue grew 41.1% year over year.
As of its latest reported balance sheet, it holds $163.14M in cash and securities against $2.15B of debt, a net debt position of $1.98B.
Halozyme Therapeutics does not currently pay a dividend.
The share price is up 86.2% over the past year. At $124.54 (the Oct 22, 2026 close) it sits near the top of its 52-week range of $61.23 to $125.10, above its 200-day moving average of $81.16.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $105.86, 15.0% below the Oct 22, 2026 close.
Frequently Asked Questions About Halozyme Therapeutics
What is the current stock price for HALO?
As of the Oct 22, 2026 close, HALO stock trades at $124.54. The 52-week range is $61.23–$125.10, with a day range of $121.62–$124.91.
What is the P/E ratio for HALO?
As of the Oct 22, 2026 close, Halozyme Therapeutics's trailing twelve-month (TTM) P/E ratio is 36.5, meaning investors pay $36.5 for every $1 of annual earnings. The forward P/E is 49.1, reflecting analyst expectations for future earnings. Halozyme Therapeutics operates in the Healthcare sector.
Does HALO pay dividends?
Halozyme Therapeutics does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for HALO?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for HALO is Buy. The average 12-month price target is $105.86, a 15.0% downside from the Oct 22, 2026 close of $124.54.
What is the market cap of HALO?
As of the Oct 22, 2026 close, Halozyme Therapeutics's market capitalization is $15.10B, classifying it as a large-cap company. Halozyme Therapeutics operates in the Healthcare sector within the Biotechnology industry.